Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hahahaha... I just want to see how all this comes together and how they move foward. Cant say I'm into using the technology for myself but to be part of what they have to offer is what has me excited.
Upon attaining initial safety and immunogenicity data from Phase 1 studies, INOVIO plans to advance INO-4800 to Phase 2 efficacy studies as rapidly as possible. In 10 weeks from funding, INOVIO has manufactured thousands of doses of INO-4800 to support on-going Phase 1 and planned Phase 2 clinical trials. In parallel, INOVIO is working to scale up the manufacturing of INO-4800. INOVIO plans to have one million doses of the vaccine available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding.
Looks to me like we are going to have 2 successful vaccines
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at th...
Source: PR Newswire (US)
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) and GeneOne Life Science (KSE:011000) today announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700 (also called GLS-5300) for MERS coronavirus (MERS-CoV). Vaccine recipients demonstrated strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg of INO-4700, a DNA vaccine that targets the MERS-CoV Spike (S) glycoprotein, delivered with intradermal CELLECTRA® device. The vaccination regimen was well-tolerated with no vaccine-associated severe adverse events (SAEs). The researchers at the Wistar Institute, Seoul National University Hospital, and the International Vaccine Institute (IVI) collaborated on this study with funding from IVI. These results were selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Conference to be held virtually from May 12-15, 2020.
Dr. J. Joseph Kim, INOVIO's President & CEO, said, "The INO-4700 Phase 1/2a clinical trial data demonstrates that our MERS DNA vaccine is able to generate robust immune responses using INOVIO's intradermal CELLECTRA delivery system. This exciting data provides a great foundation for the ongoing COVID-19 vaccine advancement as it demonstrates the power of INOVIO's delivery system and the strength of our coronavirus experience. As we have designed our COVID-19 vaccine INO-4800 using the same strategy as INO-4700, including the selection of full length Spike protein as the target and the use of intradermal CELLECTRA device, we are hopeful that the ongoing Phase 1 clinical trial with INO-4800 would generate similar clinical immune responses and safety data as we have just reported for INO-4700."
Overall, for those receiving 0.6 mg of INO-4700, 88% demonstrated seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a neutralization assay (EMC2012-Vero neutralization). Robust T cell responses were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate.
Dr. Jerome Kim, Director General of IVI, said, "IVI is pleased to join partners in reporting these findings as a result of our collaboration in the world's first vaccine candidate against MERS. These and subsequent clinical trials could pave the way for accelerated development of a DNA vaccine against MERS."
This is the 2nd study of INO-4700 (GLS-5300) in a clinical trial, the first being a 75-person study (MERS-001) of vaccine administered intramuscularly and followed by electroporation at either 0.67, 2 or 6 mg. Notably in the MERS-001 study, there was no significant difference between dose levels and vaccine induced immune responses were similar to those seen in recovered patients following natural infection (Lancet Infectious Disease, 2019). INO-4700 vaccination has previously been shown to provide 100% protection against MERS virus disease in a pathogenic monkey challenge model. INOVIO is planning to advance INO-4700 into a Phase 2 clinical trial in the Middle East with a previously announced funding of $56 million by the Coalition for Epidemic Preparedness Innovations (CEPI).
INO was following the same path as here today until right before the news dropped on a second vaccine that was related to MERS. This is the PR that drove the price up.
MERS is a strain of the coronavirus family. Same as SARS swine and COVID 19.
No. It’s even better! On the verge of having two successful vaccinations! $INO $$$$$
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at th...
Source: PR Newswire (US)
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) and GeneOne Life Science (KSE:011000) today announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700 (also called GLS-5300) for MERS coronavirus (MERS-CoV). Vaccine recipients demonstrated strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg of INO-4700, a DNA vaccine that targets the MERS-CoV Spike (S) glycoprotein, delivered with intradermal CELLECTRA® device. The vaccination regimen was well-tolerated with no vaccine-associated severe adverse events (SAEs). The researchers at the Wistar Institute, Seoul National University Hospital, and the International Vaccine Institute (IVI) collaborated on this study with funding from IVI. These results were selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Conference to be held virtually from May 12-15, 2020.
Dr. J. Joseph Kim, INOVIO's President & CEO, said, "The INO-4700 Phase 1/2a clinical trial data demonstrates that our MERS DNA vaccine is able to generate robust immune responses using INOVIO's intradermal CELLECTRA delivery system. This exciting data provides a great foundation for the ongoing COVID-19 vaccine advancement as it demonstrates the power of INOVIO's delivery system and the strength of our coronavirus experience. As we have designed our COVID-19 vaccine INO-4800 using the same strategy as INO-4700, including the selection of full length Spike protein as the target and the use of intradermal CELLECTRA device, we are hopeful that the ongoing Phase 1 clinical trial with INO-4800 would generate similar clinical immune responses and safety data as we have just reported for INO-4700."
Overall, for those receiving 0.6 mg of INO-4700, 88% demonstrated seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a neutralization assay (EMC2012-Vero neutralization). Robust T cell responses were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate.
Dr. Jerome Kim, Director General of IVI, said, "IVI is pleased to join partners in reporting these findings as a result of our collaboration in the world's first vaccine candidate against MERS. These and subsequent clinical trials could pave the way for accelerated development of a DNA vaccine against MERS."
This is the 2nd study of INO-4700 (GLS-5300) in a clinical trial, the first being a 75-person study (MERS-001) of vaccine administered intramuscularly and followed by electroporation at either 0.67, 2 or 6 mg. Notably in the MERS-001 study, there was no significant difference between dose levels and vaccine induced immune responses were similar to those seen in recovered patients following natural infection (Lancet Infectious Disease, 2019). INO-4700 vaccination has previously been shown to provide 100% protection against MERS virus disease in a pathogenic monkey challenge model. INOVIO is planning to advance INO-4700 into a Phase 2 clinical trial in the Middle East with a previously announced funding of $56 million by the Coalition for Epidemic Preparedness Innovations (CEPI).
Its posted in the news on here
New news release
NEWS!!! KABOOOOOOM!!
Finally decided to accumulate some more myself today ;) might keep grabbing as the low 3's keep popping up
Someone really wants to see this stay around 5. Interesting huh
I agree. Seems like someone is going to get the shaft and it wont be the longs.
Please help me understand this and correct me if I am wrong... A company (Citron) who historically shorts has filed a class action law suit against a company that they intentionally drove the price down on? Sounds kind of shady to me
Better look again bud!
We should be sending them a letter to thank them for the cheapies lol
I saw that. As long as the prices continue to hold it will totally blow their case apart. They have deffinetly hit panic mode. With the way INO is trading today it appears that investors are seeing through the line of negative propaganda they are trying to spill.
I think they might be SOL. Things look like they are setting up really well today to make the next leg up.
Loving this as compared to the huge run I was expecting to see this morning ;)
Your awsome. I was just going to post that ;)
Second case in point. Until we have achieved a short squeeze we will be experiencing extreme volatility. The moving average is slowly working it's way north so even if you did manage to make a mistake and buy high chances are IMO you will recover in the next 30 to 60 days. Always trade smart and use the tools at your disposal to minimize your losses. As long as you always trade within your comfort zone and follow your individual personal strategy you will always win. You might not always make money but you will learn from the losses.
Lets look at this in prospective. The company has authorized to sell $150 mil in common shares at whatever level they see fit and will only sell until that $150 mil has been achieved. Given the following points I dont see much reason the worry.
1.) We dont know if they will dump all the shares at once or over the course of a given time period. Given the funding that they have received from out side donors I would suspect that they wont be tossed on the market until they need the additional revenue to start manufacturing the vaccine.
2.) If they chose to dump all at once keep in mind at todays prices that's only 10,714,286 shares. On friday we traded 129,574,203 total shares. If this got dumped on the market all at once this would only equate to 8.2% of the total volume.
3.) On Friday we traded around $1,781,645,291.25 worth of cash transactions.
4.)now if we exclude the average short position of 65% that leaves us with $625,575,852 worth of legit trading to compensate for the $150 mil the company may or may not dump on the market.
Case in point I think we are more than fine.
On April 13, 2020, before the market opened, SCWorx announced that it had received a committed purchase order of two million COVID-19 rapid testing kits, “with provision for additional weekly orders of 2 million units for 23 weeks, valued at $35M per week.”
On this news, the Company’s share price increased by $9.77, to close at $12.02 per share on April 13, 2020.
Then, on April 17, 2020, Hindenburg Research issued a report doubting the validity of the deal, calling it "completely bogus," considering Chief Executive Officer Marc Schessel's checkered past, questionable credibility of supplier Promedical, and the relatively small size of its client Rethink My Healthcare.
As with the rest they were suspended for making false claims that they realistically could not deliver on.
If you look through the list most of these companies were on the pink sheets and were running under a pump and dump scam. They made claims that could not be backed up and rightfully deserved to be suspended. This is a completely different case that has government backing, and a product that is already being used in trials. Their will be no suspension here.
That's great news! Nex big run is coming as soon as the first shots are given to humans. Great area for consolidation and picking up some more shares for the major push.
I'll gladly hold over the weekend $8 to $15 run coming on monday $$$
I hope your right. I'm just speculating off the last run. We are definitely in for some great gains in the near future just a matter of seeing how this all plays out to get there ;)
Flush is entirely possible but wont come until tues to wed. Now if they release some nice news prior to the flush IMO we will see some nice consolidation, a massive short squeeze, and a push to new highes and beyond.
Thinking of jumping in here. What's everyone's thoughts on if that can push this back to the min $1.00 requirement by September without a RS?
Just waiting for the next buy in opportunity here. I did really good on the last run. Soon as it drops below 17 I'll be back in for the next.
Agreed. Most bio tech stocks saw a substantial pull back today after that news was released. It's a great buy opportunity at the moment!
Lots of loading at 5's. Something has to be brewing
I hope they release the audited financials soon that they discussed in the shareholders meeting. That would really jump start things here.
Looks like were setting up pretty good for the next run. My guess is next week unless we get that promised news.
Join the club lol
If you wait for the update you will miss the run. You will never be able to catch up until it's to late. Pretty safe area to bag and hold some here with minimal risk IMO
If they are who you think they are how far do you think they will let this run ;)
I see that. Some accumulation going on today